This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Carethers, J. M. Search for Related Content Social Bookmarking                         What's this?

Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor

Division of Gastroenterology UC303, MC 0063 University of California San Diego 9500 Gilman Drive, La Jolla CA 92093-0063, USA, jcarethers{at}ucsd.edu

Colorectal cancer is a prevalent disease in Western countries. While prevention through screening is the best approach to combat the development of colorectal cancer through the removal of precursor adenomas, many patients present with advanced disease that will require surgery and systemic therapy to improve survival. With reference to systemic therapy, the median survival of patients with metastatic colorectal cancer (those with tumor spread to lymph nodes or distant sites) has improved over the past three decades due to the introduction of 5-fluorouracil (5-FU), its subsequent biomodulation, and the addition other chemotherapeutic agents. There is now evidence that the biology of the colorectal tumor, in addition to the stage of colorectal cancer, may predict response to 5-FU-based therapy. More recently, systemic biological therapies that target signaling processes for tumor growth, such as epidermal growth factor receptor, and vascular endothelial growth factor, are also effective in improving patient survival with metastatic colorectal cancer. The use of a combination of systemic therapies that include chemotherapy and biologic therapy should continue to increase patient survival with metastatic colorectal cancer through appropriately designed clinical trials. Treatments based on the biology of the colorectal tumor also need to be examined through clinical trials.

Key Words: colorectal cancer • chemotherapy • biologic therapy • bevacizumab • cetuximab • 5-fluorouracil • epidermal growth factor receptor • tyrosine kinase inhibitor • vascular endothelial growth factor

References

• Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J. et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol 26: 1626-34.[Abstract/Free Full Text]
• Arnold, C.N., Goel, A. and Boland, C.R. (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluoruracil in colorectal cancer cell lines, Int J Cancer 106: 66-73.[CrossRef][Medline] [Order article via Infotrieve]
• Berlin, J., Posey, J., Tchekmedyian, S., Hu, E., Chan, D., Malik, I. et al. (2007) Panitumumab with irinotecan/leucovorin/5-fluoruracil for first-line treatment of metastatic colorectal cacner, Clin Colorectal Cancer 6: 427-432.[Medline] [Order article via Infotrieve]
• Best, L., Simmonds, P., Baughan, C., Buchanan, R., Davis, C., Fentiman, I. et al. (2000) Colorectal meta-analysis Collaboration. Palliative chemotherapy for advanced or metastatic colorectal cancer, Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD001545. DOI: 10.1002/14651858.CD001545. Accessed April 8, 2008.
• Boland, C.R., Sinicrope, F.A., Brenner, D.E. and Carethers, J.M. (2000) Colorectal cancer prevention and treatment, Gastroenterology 118: S115-S128.[CrossRef][Medline] [Order article via Infotrieve]
• Carethers, J.M., Chauhan, D.P., Fink, D., Nebel, S., Bresalier, R.S., Howell, S.B. et al. (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil, Gastroenterology 117: 123-131.[CrossRef][Medline] [Order article via Infotrieve]
• Carethers, J.M., Hawn, M.T., Chauhan, D.P., Luce, M.C., Marra, G., Koi, M. et al. (1996) Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine, J Clin Invest 98: 199-206.[Medline] [Order article via Infotrieve]
• Carethers, J.M., Smith, E.J., Behling, C.A., Nguyen, L., Tajima, A., Doctolero, R.T. et al. (2004) Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer, Gastroenterology 126: 394-401.[CrossRef][Medline] [Order article via Infotrieve]
• Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M. et al. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose, N Engl J Med 358: 1109-1117.[Abstract/Free Full Text]
• Chung, K.Y., Shia, J., Kemeny, N.E., Shah, M., Schwartz, G.K., Tse, A. et al. (2005) Cetuximab shows activity in colorectal cancer patients with turmos that do not express the epidermal growth factor receptor by immunohistochemistry, J Clin Oncol 23: 1803-1810.[Abstract/Free Full Text]
• Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I. and Van Cutsem, E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, New Engl J Med 351: 337-45.[Abstract/Free Full Text]
• de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J. et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol 18(16): 2938-2947.[Abstract/Free Full Text]
• de Vos tot Nedervee Cappel, W.H., Neulenbeld, H.J., Keibeuker, J.H., Nagengast, F.M., Menko, F.H., Griffioen, G. et al. (2004 ) Survival after adjuvant 5-FU treatment for stage III coon cancer in hereditary nonpolyposis colorectal cancer, In J Cancer 109: 468-471.
• Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P. et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet 355(9209): 1041-1047.[CrossRef][Medline] [Order article via Infotrieve]
• Ferrara, N., Gerber, H.P. and LeCounter, J. (2003) The biology of VEGF and its receptors, Nat Med 9: 669-676.[CrossRef][Medline] [Order article via Infotrieve]
• Gill, S., Loprinzi, C.L., Sargent, D.J., Thomé, S.D., Alberts, S.R., Haller, D.G. et al. (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22: 1797-806.[Abstract/Free Full Text]
• Goldberg, R.M., Sargent, D.J., Morton, R.F., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K. et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol 22(1): 23-30.[Abstract/Free Full Text]
• Grady, W.M. and Carethers, J.M. (2008) Genomic instability and molecular pathogenesis of colorectal cancer, Gastroenterology (in press).
• Hardcastle, J.D., Chamberlain, J.O., Robinson, M. He., Moss, S.M., Amar, S.S., Balfour, T.W. et al. (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet 348: 1472.[CrossRef][Medline] [Order article via Infotrieve]
• Hoskins, J.M., Goldberg, R.M., Qu, P., Ibrahim, J.G. and McLeod, H.L. (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters, J Natl Cancer Inst 99: 1290-1295.[Abstract/Free Full Text]
• Huang, S., Armstrong, E.A., Benavente, S., Chinnaiyan, P. and Harari, P.M. (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR); combining anti-EGFR antibody with tyrosine kinase inhibitor, Cancer Res 64: 5355-5362.[Abstract/Free Full Text]
• Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med 350(23): 2335-42.[Abstract/Free Full Text]
• Ingraham, H.A., Tseng, B.Y. and Goulian, M. (1980) Mechanism for exclusion of 5-fluorouracil from DNA, Cancer Res 40: 998-1001.[Abstract/Free Full Text]
• Jemel, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M.J. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.[Abstract/Free Full Text]
• Jonker, D.J., O'Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.J. et al. (2007) Cetuximab for the treatment of colorectal cancer, N Engl J Med 357(20): 2040-2048.[Abstract/Free Full Text]
• Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M., Cubiella, J. et al. (2006) Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer, Gut 55: 848-855.[Abstract/Free Full Text]
• Klein, C.E., Gupta, E., Reid, J.M., Atherton, P.J., Sloan, J.A., Pitot, H.C. et al. (2002) Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucoronideClin Pharmacol Ther 72: 638-47.[CrossRef][Medline] [Order article via Infotrieve]
• Koopman, M., Antonini, N.F., Douma, J., Wals, J., Honkoop, A.H., Erdkamp, F.L. et al. (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial, Lancet 370: 135-142.[CrossRef][Medline] [Order article via Infotrieve]
• Kronborg, O., Fenger, C., Olsen, J., Jørgensen, O.D. and Søndergaard, O. (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test, Lancet 348: 1467-71.[CrossRef][Medline] [Order article via Infotrieve]
• Kuo, T., Cho, C.D., Hasley, J., Wakelee, H.A., Advani, R.H., Ford, J.M. et al. (2005) Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cacner, J Clin Oncol 23: 5613-5619.[Abstract/Free Full Text]
• Laurie, J.A., Moertel, C.G., Fleming, T.R., Wieand, H.S., Leigh, J.E., Rubin, J. et al. (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil, J Clin Oncology 7: 1447-1456.[Abstract]
• Lièvre, A., Bachet, J.B., Boige, V., Cayre, A., Le Corre, D., Buc, E. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol 26: 374-379.[Abstract/Free Full Text]
• Lonn, U. and Lonn, S. (1986) DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines, Cancer Res 46: 3866-3870.[Abstract/Free Full Text]
• Mandel, J.S., Bond, J.H., Church, T.R., Snover, D.C., Bradley, G.M., Schuman, L.M. and Ederer, F. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328: 1365-71.[Abstract/Free Full Text]
• Meyers, M., Wagner, M.W., Mazurek, A., Schmutte, C., Fishel, R. and Boothman, D.A. (2005) DNA mismatch repair-dependent response to fluoropyrimidine-generated damage, J Biol Chem 280: 5516-5526.[Abstract/Free Full Text]
• Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Goodman, P.J. et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Eng J Med 322: 352-358.[Abstract]
• Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Tangen, C.M. et al. (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report, Ann Intern Med 122: 321-326.[Abstract/Free Full Text]
• Papouli, E., Cejka, P. and Jiricny, J. (2004) Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells, Cancer Res 64: 3391-3394.[Abstract/Free Full Text]
• Parker, W.B. and Cheng, Y.C. (1990) Metabolism and mechanism of action of 5-fluorouracil, Pharmac Ther 48: 381-395.[CrossRef][Medline] [Order article via Infotrieve]
• Parker, W.B., Kennedy, K.A. and Klubes, P. (1987) Dissociation of 5-fluorouracil-induced DNA fragmentation from either its incorporation into DNA or its cytotoxicity in murine T-lymphoma (S-49) cells, Cancer Res 47: 979-982.[Abstract/Free Full Text]
• Petrelli, N., Douglass Jr, H.O., Herrera, L., Russell, D., Stablein, D.M., Bruckner, H.W. et al. (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group, J Clin Oncol 7(10): 1419-1426.[Abstract]
• Ponz-Sarvise, M., Rodriguez, J., Viudez, A., Chopitea, A., Calvo, A., Garcia-Foncillas, J. et al. (2007) Epidermal growth factor receptor inhibitors in colorectal cacner treatment: what's new, World J Gastroenterol 13: 5877-5887.[Medline] [Order article via Infotrieve]
• Raymond, E., Faivre, S., Chaney, S., Woynarowski, J. and Cvitkovic, E. (2002) Cellular and molecular pharmacology of oxaliplatin, Mol Cancer Ther 1: 227-235.[Abstract/Free Full Text]
• Ribic, C.M., Sargent, D.J., Moore, M.J., Thibodeau, S.N., French, A.J., Goldberg, R.M. et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med 349: 247-257.[Abstract/Free Full Text]
• Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R. et al. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cacner, Lancert 352: 1407-1412.[CrossRef]
• Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J. et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med 343(13): 905-914.[Abstract/Free Full Text]
• Seymour, M.T., Maughan, T.S., Ledermann, J.A., Topham, C., James, R., Gwyther, S.J. et al. (2007) FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, Lancet 370: 143-152.[CrossRef][Medline] [Order article via Infotrieve]
• Strumberg, D., Richly, H., Hilger, R.A., Schleucher, N., Korfee, S., Tewes, M. et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors, J Clin Oncol 23: 965-972.[Abstract/Free Full Text]
• Tajima, A., Hess, M.T., Cabrera, B.L., Kolodner, R.D. and Carethers, J.M. (2004) The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance, Gastroenterology 127: 1678-1684.[CrossRef]
• Townsley, C.A., Major, P., Siu, L.L., Dancey, J., Chen, E., Pond, G.R. et al. (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer, Br J Cancer 94: 1136-1143.[CrossRef][Medline] [Order article via Infotrieve]
• Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B. et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compated with best supportive care alon in patients with chemotherapy-refractory metastatic colorectal cacner, J Clin Oncol 25: 1658-1664.[Abstract/Free Full Text]
• Verones, M.L., Sun, W., Giantonio, B., Berlin, J., Shults, J., Davis, L. et al. (2005) A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer, Br J Cancer 92: 1846-1849.[CrossRef][Medline] [Order article via Infotrieve]
• Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R. and Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat Rev Drug Discov 5: 835-844.[CrossRef][Medline] [Order article via Infotrieve]
• World Health Organization. Available at: http://www.who.int/mediacentre/news/releases/2003/pr27/en/. (accessed April 8, 2008).
• Yu, C., Bruzek, L.M., Meng, X.W., Gores, G.J., Carter, C.A., Kaufmann, S.H. et al. (2005) The role of Mcl-1 down-regulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006, Oncogene 24: 6861-6869.[CrossRef][Medline] [Order article via Infotrieve]

Therapeutic Advances in Gastroenterology, Vol. 1, No. 1, 33-42 (2008)
DOI: 10.1177/1756283X08093607


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Carethers, J. M. Search for Related Content Social Bookmarking                         What's this?